The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

Inclusion Criteria: * Have a diagnosis of Type 1 or Type 2 diabetes and confirmed peripheral neuropathy * Have adequate circulation to the foot * Have an ulcer area at screening up to 6 cm\^2 * Up to date on all age-appropriate cancer screenings per local standards Exclusion Criteria: * Have current evidence of osteomyelitis, cellulitis, or evidence of systemic infection * Have gangrene present on any part of the affected foot * Known peripheral arterial disease requiring revascularization * Have a glycated hemoglobin A1C level of greater than (\>) 15% assessed at screening * Are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents * Have active malignancy or any history of a malignancy * Use of oral antibiotics at the time of randomization for any reason in participants to be enrolled in Cohorts A, B, E, and any additional uninfected patient cohorts